Catalyst Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Balaji Prasad - Barclays Bank - Analyst : Great. So with all these launches, what does it mean to for your outlook for 2025? And what are the key priorities for you as you look to execute this year too and what we need to look out for?

Question: Balaji Prasad - Barclays Bank - Analyst : Got it. Great. So in your opening remarks, you spoke about the the launch and the growth that you have seen over consecutive quarters. So what's going to allow you to continue to maintain that very impressive trajectory on into 2025? And then maybe taking a step further on, you spoke about this broad market opportunity, the $1 billion market operationally. So how would you be able to realize.

Question: Balaji Prasad - Barclays Bank - Analyst : Got it. Maybe a quick comment around the recent settlement with Teva on the product and what's your view around the longer-term -- the longer-term potential?

Question: Balaji Prasad - Barclays Bank - Analyst : Great. Having covered the generics industry too from a long time, what we have seen typically is that one settlement with a major generic company kind of precedes other settlements too? Is that a reasonable assumption in this case?

Question: Balaji Prasad - Barclays Bank - Analyst : It is. Okay. Great. And so can you just remind us of the quick terms of the Teva settlement?

Question: Balaji Prasad - Barclays Bank - Analyst : Got it. And when would we expect to hear about the other two companies (inaudible) . REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 11, 2025 / 5:00PM, CPRX.OQ - Catalyst Pharmaceuticals Inc at Barclays Global Healthcare Conference

Question: Balaji Prasad - Barclays Bank - Analyst : Fair enough. And maybe shifting to AGAMREE and Duchenne's. Could you talk about how AGAMREE fits into the treatment paradigm for DMD patients currently?

Question: Balaji Prasad - Barclays Bank - Analyst : Understood. So as you target trying to get this 30% of patients onto a corticosteroid, what are the key steps and milestones that we can look forward to over the course of this -- over the course of this aim or goal, what are the key steps we can look forward to?

Question: Balaji Prasad - Barclays Bank - Analyst : Sure. Got it. Maybe just to add another layer of questioning around this segment with new therapies, be it sRNA or gene therapies being developed for DMD. How do you see the longer-term view for how the treatment paradigm for DMD, the whole landscape is going to evolve, how do you progress?

Question: Balaji Prasad - Barclays Bank - Analyst : Got it. Yes. Shifting from this -- from AGAMREE to Fycompa. So speak about 2025 and how we should think about the -- about the product on potential generic entry. And I know you also spoken about the erosion trajectory in the setting -- so what kind of details do we need to look for that can help us gauge the product out?

Question: Balaji Prasad - Barclays Bank - Analyst : What details can we look for to guage the product (inaudible) REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 11, 2025 / 5:00PM, CPRX.OQ - Catalyst Pharmaceuticals Inc at Barclays Global Healthcare Conference

Question: Balaji Prasad - Barclays Bank - Analyst : Shifting towards other parts of the business. So you have around $500-plus million cash on hand on the balance sheet. Speak to us about your business development plans for the next couple of years? And what are your key target areas and assets that you are pursuing?

Question: Balaji Prasad - Barclays Bank - Analyst : Understood. And do you see enough opportunities to pursue. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 11, 2025 / 5:00PM, CPRX.OQ - Catalyst Pharmaceuticals Inc at Barclays Global Healthcare Conference

Question: Balaji Prasad - Barclays Bank - Analyst : And maybe some comments around the valuations that you're seeing, what kind of valuations you're seeing? Is it reasonable?

Question: Balaji Prasad - Barclays Bank - Analyst : Understood. Maybe a final question around your plans to invest in portfolio diversification. And what does this mean? What does it entail? And any focus there?

Question: Balaji Prasad - Barclays Bank - Analyst : Got it. Great. So Richard and Steve, thank you so much for joining us today. And I do wish you a very productive conference. I appreciate you joining the conference.